Alexandre Zanghellini co-founded Arzeda and leads the team as CEO and Vice President, Research. His responsibilities include overseeing scientific and technology development, defining Arzeda’s business strategy and securing financial and human resource necessary for its execution. Alexandre is an internationally recognized protein design expert. He was the early developer of Arzeda’s protein design software Archytas™ for enzyme design, and is leading the development of Arzeda’s metabolic pathway design software Scylax™. He is deeply involved both with Arzeda’s technology platform development and its applications to the commercial world. Before Arzeda, Alexandre led bioinformatics at Cellectis (NASDAQ: CLLS) a publicly traded protein engineering and gene editing company.
Alexandre strongly believes the convergence of big compute, machine learning, DNA synthesis and high throughput screening represent an inflexion point in human history, and that the rationale design of new proteins will play a key role in solving some of humanity’s biggest societal challenges from improving human health to combating global warming. Alexandre holds a Ph.D. in Biochemistry from University of Washington, a M.S in Computer Science (Artificial Intelligence) and BS in Applied Mathematics, both from University of Paris, and a M.Eng. from ENSTA/ParisTech.
Current role